- UroToday Home
- Recent Abstracts
- Urologic Oncology
Prostate Cancer
Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence - Abstract
February 3, 2012
Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer - Abstract
February 3, 2012
An opposed matched field IMRT technique for prostate cancer patients with bilateral prosthetic hips - Abstract
February 3, 2012
A study of segment weight optimization with the CMS XiO step-and-shoot IMRT technique for prostate cancer - Abstract
February 3, 2012
Quality of life issues in men undergoing androgen deprivation therapy: A review - Abstract
February 3, 2012
Impact of androgen deprivation therapy on sexual function - Abstract
February 3, 2012
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer - Abstract
February 3, 2012
Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study - Abstract
February 3, 2012
Active surveillance in prostate cancer - Abstract
February 3, 2012
PCA: Prostate cancer, patient-centred approach or both? - Abstract
February 3, 2012
GU Cancers Symposium 2012 - Approved agents and related trials - Session Highlights
February 3, 2012
GU Cancers Symposium 2012 - Sequencing of therapies in men with castration-resistant prostate cancer - Session Highlights
February 3, 2012
GU Cancers Symposium 2012 - Castration-resistant prostate cancer: Novel targets, agents, and trials - Session Highlights
February 3, 2012
Myriad’s Prolaris® test shown to significantly predict biochemical recurrence risk after prostatectomy
February 3, 2012
GU Cancers Symposium 2012 - Role of dose escalation and supplemental androgen deprivation - Session Highlights
February 3, 2012